Abiopharma

🔍 Cunningham Andrea Lee (Director)

Company: Trade Desk, Inc. (TTD)

Report Date: 2026-05-04

Detailed Transactions and Holdings:

• Acquired 6,110 shares of Class A Common Stock (Direct)
  Date: 2026-05-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 11,193.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 1,053 shares of Class A Common Stock at $23.73 per share (Direct)
  Date: 2026-05-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 12,246.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Acquired 210 shares of Class A Common Stock at $23.73 per share (Direct)
  Date: 2026-05-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 12,456.00 | transaction_form_type: 4 | Footnotes: F5, F4
• Acquired 526 shares of Class A Common Stock at $23.73 per share (Direct)
  Date: 2026-05-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 12,982.00 | transaction_form_type: 4 | Footnotes: F7, F4
• Acquired 11,051 shares of Stock Option (Right to Buy) at $24.1 per share (Derivative)
  Date: 2026-05-04 | Code: A | Expires: 2036-05-04 | equity_swap_involved: 0 | shares_owned_after: 11,051.00 | transaction_form_type: 4 | Footnotes: F10, F9
• Acquired 1,905 shares of Stock Option (Right to Buy) at $24.1 per share (Derivative)
  Date: 2026-05-04 | Code: A | Expires: 2036-05-04 | equity_swap_involved: 0 | shares_owned_after: 1,905.00 | transaction_form_type: 4 | Footnotes: F11, F9
• Acquired 381 shares of Stock Option (Right to Buy) at $24.1 per share (Derivative)
  Date: 2026-05-04 | Code: A | Expires: 2036-05-04 | equity_swap_involved: 0 | shares_owned_after: 381.00 | transaction_form_type: 4 | Footnotes: F11, F13
• Acquired 952 shares of Stock Option (Right to Buy) at $24.1 per share (Derivative)
  Date: 2026-05-04 | Code: A | Expires: 2036-05-04 | equity_swap_involved: 0 | shares_owned_after: 952.00 | transaction_form_type: 4 | Footnotes: F11, F15

Footnotes:

• F1: Grant of restricted stock award under the Issuer's 2025 Incentive Award Plan. The shares vest in four equal installments at the earlier of, for each such installment, (i) the date of the Issuer's applicable regularly scheduled quarterly Corporate Board meeting for the next four quarters from the date of grant or (ii) the date of each of the next four corresponding quarterly anniversaries of the date of grant, provided all then unvested shares shall vest in full on the date of the Issuer's next annual meeting of stockholders, all subject to the Reporting Person's continuous service as a member of the board of directors immediately prior to such date.
• F2: This restricted stock award was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy as an annual director equity grant.
• F3: This restricted stock award was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of director retainer and meeting fees of $25,000.
• F4: This price represents the average closing stock price for a share of the Issuer's Class A Common Stock for forty-five consecutive trading days ending on, and including, the grant date. This price was used to calculate the number of restricted stock awards granted.
• F5: Grant of restricted stock award under the Issuer's 2025 Incentive Award Plan. The shares vest in four equal installments at the earlier of, for each such installment, (i) the date of the Issuer's applicable regularly scheduled quarterly Corporate Board meeting for the next four quarters from the date of grant or (ii) the date of each of the next four corresponding quarterly anniversaries of the date of grant, provided all then unvested shares shall vest in full on the date of the Issuer's next annual meeting of stockholders, all subject to the Reporting Person's continuous service as a member of the compensation committee immediately prior to such date.
• F6: This restricted stock award was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of director retainer and meeting fees of $5,000.
• F7: Grant of restricted stock award under the Issuer's 2025 Incentive Award Plan. The shares vest in four equal installments at the earlier of, for each such installment, (i) the date of the Issuer's applicable regularly scheduled quarterly Corporate Board meeting for the next four quarters from the date of grant or (ii) the date of each of the next four corresponding quarterly anniversaries of the date of grant, provided all then unvested shares shall vest in full on the date of the Issuer's next annual meeting of stockholders, all subject to the Reporting Person's continuous service as a member of the nominating and corporate governance committee immediately prior to such date.
• F8: This restricted stock award was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of director retainer and meeting fees of $12,500.
• F9: Grant of option to purchase Class A Common Stock under the Issuer's 2025 Incentive Award Plan. The shares subject to the option vest in four equal installments at the earlier of, for each such installment, (i) the date of the Issuer's applicable regularly scheduled quarterly Corporate Board meeting for the next four quarters from the date of grant or (ii) the date of each of the next four corresponding quarterly anniversaries of the date of grant, provided all then unvested shares shall vest in full on the date of the Issuer's next annual meeting of stockholders, all subject to the Reporting Person's continuous service as a member of the board of directors immediately prior to such date.
• F10: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy as an annual director equity grant.
• F11: This price represents the Black-Scholes value of an option using the average closing stock price for a share of the Issuer's Class A Common Stock for forty-five consecutive trading days ending on, and including, the grant date. This price was used to calculate the number of shares subject to the option granted.
• F12: These stock options were issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of director retainer and meeting fees of $25,000.
• F13: Grant of option to purchase Class A Common Stock under the Issuer's 2025 Incentive Award Plan. The shares subject to the option vest in four equal installments at the earlier of, for each such installment, (i) the date of the Issuer's applicable regularly scheduled quarterly Corporate Board meeting for the next four quarters from the date of grant or (ii) the date of each of the next four corresponding quarterly anniversaries of the date of grant, provided all then unvested shares shall vest in full on the date of the Issuer's next annual meeting of stockholders, all subject to the Reporting Person's continuous service as a member of the compensation committee of the board of directors immediately prior to such date.
• F14: These stock options were issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of director retainer and meeting fees of $5,000.
• F15: Grant of option to purchase Class A Common Stock under the Issuer's 2025 Incentive Award Plan. The shares subject to the option vest in four equal installments at the earlier of, for each such installment, (i) the date of the Issuer's applicable regularly scheduled quarterly Corporate Board meeting for the next four quarters from the date of grant or (ii) the date of each of the next four corresponding quarterly anniversaries of the date of grant, provided all then unvested shares shall vest in full on the date of the Issuer's next annual meeting of stockholders, all subject to the Reporting Person's continuous service as a member of the nominating and corporate governance committee of the board of directors immediately prior to such date.
• F16: These stock options were issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of director retainer and meeting fees of $12,500.